{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:48Z","timestamp":1792372128622,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA077598"],"award-info":[{"award-number":["P30CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtct.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T18:02:14Z","timestamp":1720720934000},"page":"1005.e1-1005.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita\/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation"],"prefix":"10.1016","volume":"30","author":[{"given":"Marketa","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-3849","authenticated-orcid":false,"given":"Svatava","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.","family":"Tryon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Vercellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-8870","authenticated-orcid":false,"given":"Roy L.","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Srikanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Terezakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-911X","authenticated-orcid":false,"given":"Christen L.","family":"Ebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.07.007_bib0001","article-title":"Dyskeratosis Congenita and Related Telomere Biology Disorders","author":"Savage","year":"1993"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0002","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/hematology.2022000394","article-title":"Dyskeratosis congenita and telomere biology disorders","volume":"2022","author":"Savage","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"10.1016\/j.jtct.2024.07.007_bib0003","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2014-05-526285","article-title":"Bone marrow failure and the telomeropathies","volume":"124","author":"Townsley","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0004","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2016.03.001","article-title":"Survival after hematopoietic stem cell transplant in patients with dyskeratosis congenita: systematic review of the literature","volume":"22","author":"Barbaro","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.007_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2014.01.001","article-title":"Crosstalk between telomere maintenance and radiation effects: A key player in the process of radiation-induced carcinogenesis","volume":"760","author":"Shim","year":"2014","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.007_bib0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1700674","article-title":"Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation","volume":"19","author":"Yabe","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.07.007_bib0008","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/bmt.2013.35","article-title":"Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure","volume":"48","author":"Ayas","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2024.07.007_bib0009","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bbmt.2013.05.021","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita","volume":"19","author":"Gadalla","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/bmt.2010.65","article-title":"Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita","volume":"46","author":"Dietz","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.007_bib0011","first-page":"650","article-title":"Gentamicin therapy","volume":"8","author":"Devine","year":"1974","journal-title":"Drug Intell Clin Pharm"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.007_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.007_bib0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bbmt.2005.02.004","article-title":"Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source","volume":"11","author":"Barker","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"282","key":"10.1016\/j.jtct.2024.07.007_bib0014","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Journal of the American Statistical Association"},{"issue":"19","key":"10.1016\/j.jtct.2024.07.007_bib0015","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.3390\/ijms21197196","article-title":"Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita","volume":"21","author":"Vieri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.007_bib0016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.12748","article-title":"Response to androgen therapy in patients with dyskeratosis congenita","volume":"165","author":"Khincha","year":"2014","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2024.07.007_bib0017","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.007_bib0018","first-page":"111","article-title":"Pediatric bone marrow transplantation for leukemia and aplastic anemia. Report of 222 cases transplanted in a single center","volume":"31","author":"Gluckman","year":"1989","journal-title":"Nouv Rev Fr Hematol (1978)"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.007_bib0019","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00043426-198822000-00002","article-title":"Bone marrow transplantation for aplastic anemia associated with dyskeratosis congenita","volume":"10","author":"Conter","year":"1988","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00320601","article-title":"Marrow transplantation for pancytopenia in dyskeratosis congenita","volume":"51","author":"Mahmoud","year":"1985","journal-title":"Blut"},{"issue":"11","key":"10.1016\/j.jtct.2024.07.007_bib0021","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archderm.1985.01660110072019","article-title":"Dyskeratosis congenita in a girl simulating chronic graft-vs-host disease","volume":"121","author":"Ling","year":"1985","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.007_bib0022","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1046\/j.1365-2141.1996.424984.x","article-title":"Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita","volume":"92","author":"Langston","year":"1996","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.07.007_bib0023","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bmt.1705839","article-title":"Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan","volume":"40","author":"Amarasinghe","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.007_bib0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2141.2002.03835_2.x","article-title":"Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen","volume":"119","author":"Nobili","year":"2002","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2024.07.007_bib0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.bmt.1703931","article-title":"Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita","volume":"31","author":"Dror","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.007_bib0026","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bbmt.2006.11.015","article-title":"Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure","volume":"13","author":"Ostronoff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.007_bib0027","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.bmt.1705171","article-title":"Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen","volume":"36","author":"Brazzola","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.007_bib0028","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/j.transproceed.2013.02.137","article-title":"Fludarabine, low-dose cyclophosphamide and rabbit antithymocyte globulin allowed stable engraftment after allogeneic peripheral blood stem cell transplantation for poly-transfused dyskeratosis congenita patient: case report","volume":"45","author":"Colita","year":"2013","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.007_bib0029","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000318721","article-title":"Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita","volume":"124","author":"Vuong","year":"2010","journal-title":"Acta Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2024.07.007_bib0030","doi-asserted-by":"crossref","first-page":"e29177","DOI":"10.1002\/pbc.29177","article-title":"Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review","volume":"68","author":"Bhoopalan","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pbc.20696","article-title":"Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin","volume":"49","author":"Ayas","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.jtct.2024.07.007_bib0032","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-017-3041-7","article-title":"Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes","volume":"96","author":"Li","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.007_bib0033","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bbmt.2016.01.026","article-title":"A reduced-intensity conditioning regimen for patients with dyskeratosis congenita undergoing hematopoietic stem cell transplantation","volume":"22","author":"Nelson","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.07.007_bib0034","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.bbmt.2019.07.007","article-title":"Outcomes of hematopoietic cell transplantation in patients with germline SAMD9\/SAMD9L mutations","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0035","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/MPH.0000000000000208","article-title":"Diffuse hemorrhagic colitis in a patient with dyskeratosis congenita after nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Ehlert","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0036","doi-asserted-by":"crossref","first-page":"e27476","DOI":"10.1002\/pbc.27476","article-title":"Unrelated allogeneic hematopoietic stem cell transplantation in a patient with Revesz syndrome, a severe variant of dyskeratosis congenita","volume":"66","author":"Watanabe","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.007_bib0037","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/MPH.0b013e318279e5ca","article-title":"Irreversible leukoencephalopathy after reduced-intensity stem cell transplantation in a dyskeratosis congenita patient with TINF2 mutation","volume":"35","author":"Isoda","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.007_bib0038","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1097\/MPH.0000000000000844","article-title":"Allogeneic hematopoietic cell transplantation for dyskeratosis congenita: a report of 3 cases","volume":"39","author":"Tamura","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0039","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1111\/petr.12172","article-title":"Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation","volume":"18","author":"O'Connell","year":"2014","journal-title":"Pediatr Transplant"},{"issue":"13","key":"10.1016\/j.jtct.2024.07.007_bib0040","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.3390\/ijms20133261","article-title":"Complications for a Hoyeraal-Hreidarsson syndrome patient with a germline DKC1 A353V variant undergoing unrelated peripheral blood stem cell transplantation","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.007_bib0041","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bmt.2015.352","article-title":"TCR \u03b1\u03b2 and CD19-depleted haploidentical stem cell transplant with reduced intensity conditioning for Hoyeraal-Hreidarsson syndrome with RTEL1 mutation","volume":"51","author":"Bhattacharyya","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.007_bib0042","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.bmt.1701567","article-title":"Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation","volume":"23","author":"Ghavamzadeh","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0043","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.15495","article-title":"Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita","volume":"183","author":"Fioredda","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0044","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3324\/haematol.2010.027839","article-title":"Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia","volume":"96","author":"Bizzetto","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.007_bib0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/sci.2019.10.04","article-title":"Cord blood transplantation for bone marrow failure syndromes: state of art","volume":"6","author":"Pagliuca","year":"2019","journal-title":"Stem Cell Investig"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.007_bib0046","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bmt.2016.301","article-title":"Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia","volume":"52","author":"Thakar","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.007_bib0047","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbmt.2016.11.006","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with Fanconi anemia","volume":"23","author":"Bonfim","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0048","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/bloodadvances.2021005628","article-title":"TCR \u03b1\u03b2\/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders","volume":"6","author":"Merli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.007_bib0049","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/hematology.2019000020","article-title":"Monitoring and treatment of MDS in genetically susceptible persons","volume":"2019","author":"Davies","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.007_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.01.075","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7286","key":"10.1016\/j.jtct.2024.07.007_bib0051","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nature08792","article-title":"Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients","volume":"464","author":"Agarwal","year":"2010","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.007_bib0052","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/bloodadvances.2020001848","article-title":"Chemical inhibition of PAPD5\/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita","volume":"4","author":"Shukla","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.007_bib0053","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2018-11-885368","article-title":"Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita","volume":"133","author":"Fok","year":"2019","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400530X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400530X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T18:05:19Z","timestamp":1759428319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672400530X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S266663672400530X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita\/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}